StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

ProQR Therapeutics's ebitda for the twelve months ending Sep 30, 2022 was -€67.70M. For fiscal 2021 it was -€54.88M. The highest annual figure on record is -€26.52M in fiscal 2015.

Annual ebitda

PeriodPeriod endValueChange
FY2021Dec 31, 2021-€54.88M–
FY2020Dec 31, 2020-€40.01M–
FY2019Dec 31, 2019-€55.39M–
FY2018Dec 31, 2018-€35.30M–
FY2017Dec 31, 2017-€39.43M–
FY2016Dec 31, 2016-€38.33M–
FY2015Dec 31, 2015-€26.52M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2023Sep 30, 2023-€6.75M–
Q2 FY2023Jun 30, 2023-€8.22M–
Q1 FY2023Mar 31, 2023-€8.84M–
Q3 FY2022Sep 30, 2022-€19.21M–
Q2 FY2022Jun 30, 2022-€15.24M–
Q1 FY2022Mar 31, 2022-€16.47M–
Q4 FY2021Dec 31, 2021-€16.78M–
Q3 FY2021Sep 30, 2021-€14.01M–
Q2 FY2021Jun 30, 2021-€12.60M–
Q1 FY2021Mar 31, 2021-€11.47M–
Q4 FY2020Dec 31, 2020-€11.02M–
Q3 FY2020Sep 30, 2020-€10.21M–
Q2 FY2020Jun 30, 2020-€2.83M–
Q1 FY2020Mar 31, 2020-€15.96M–
Q4 FY2019Dec 31, 2019-€16.92M–
Q3 FY2019Sep 30, 2019-€12.94M–
Q2 FY2019Jun 30, 2019-€11.32M–
Q1 FY2019Mar 31, 2019-€14.22M–
Q4 FY2018Dec 31, 2018-€12.58M–
Q3 FY2018Sep 30, 2018-€5.68M–
Q2 FY2018Jun 30, 2018-€7.43M–
Q2 FY2017Jun 30, 2017-€9.91M–

More ProQR Therapeutics figures

See a number that looks wrong?